CME Presentations

Asthma


Presentations


Speakers


CME Information

What are Epithelial Alarmins and Why are They Important? – New Understanding of Severe Asthma Pathophysiology and the Inflammatory Cascade


NJH LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Define the epithelial alarmins and their pivotal role in inflammation in asthma
  • Describe how the epithelial alarmins impact both T2 and non-T2 downstream inflammation in asthma
  • Explain how therapies, such as anti-TSLP, would be expected to modulate airway inflammation in patients with either a T2-high or T2-low phenotype
  • Evaluate the results of clinical trials of novel therapies that target the epithelial alarmins
This activity is provided by National Jewish Health.

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Credit Available

  • Physicians – 1.0 AMA PRA Category 1 Credit
All other health care professionals completing this course will be issued a statement of participation.

Target Audience

Pulmonologists, allergists, nurse practitioners, and physician assistants in these specialties.

Duration of Activity

June 9, 2021 – June 9, 2022

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Education.

Faculty Disclosures

Michael E. Wechsler, MD, MMSc declares he is a consultant and investigator for AstraZeneca and a consultant for Amgen.
Flavia Cecilia Lega Hoyte, MD declares she is on an advisory board for AstraZeneca.

Planners and Reviewers

Meghan Brenner, MA declares she has no relevant financial relationships.
Anthony Gerber, MD declares he is a consultant for BeiGene, Pliant Therapeutics, and Biosciences Pharma.
Andrea Harshman, MHA, CHCP, CMP-HC declares she has no relevant financial relationships.
Harold S Nelson, MD declares he is a consultant for ALK and on a data safety monitoring board for AstraZeneca.
Lauren Rieck declares she has no relevant financial relationships.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.